EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpoints

Nathan Braniff, Tanvi Joshi iD, Tyler Cassidy, Michael Trogdon, Rukmini Kumar, Kamrine Poels iD, Richard Allen, Cynthia J Musante iD, Blerta Shtylla

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.13270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Nathan Braniff und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacometrics & Systems Pharmacology, Pfizer Inc., La Jolla, California, USA. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Network Pharmacology. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In drug development, quantitative systems pharmacology (QSP) models are becoming an increasingly important mathematical tool for understanding response variability and for generating predictions to inform development decisions. Virtual populations are essential for sampling uncertainty and potential variability in QSP model predictions, but many clinical efficacy endpoints can be difficult to capture with QSP models that typically rely on mechanistic biomarkers. In oncology, challenges are particularly significant when connecting tumor size with time‐to‐event endpoints like progression‐free survival while also accounting for censoring due to consent withdrawal, loss in follow‐up, or safety criteria. Here, we expand on our prior work and propose an extended virtual population selection algorithm that can jointly match tumor burden dynamics and progression‐free survival times in the presence of censoring. We illustrate the core components of our algorithm through simulation and calibration of a signaling pathway model that was fitted to clinical data for a small molecule targeted inhibitor. This methodology provides an approach that can be tailored to other virtual population simulations aiming to match survival endpoints for solid‐tumor clinical datasets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsNetwork PharmacologyHumansAlgorithmsComputer SimulationProgression-Free SurvivalCalibrationDrug DevelopmentTumor BurdenModels, Biological

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Pharmacometrics & Systems Pharmacology, Pfizer Inc., La Jolla, California, USA.
  • Vantage Research Inc., Lewes, Delaware, USA.
  • Pharmacometrics & Systems Pharmacology, Pfizer Inc., Cambridge, Massachusetts, USA.

ORCID-Profile: Tanvi Joshi, Kamrine Poels, Cynthia J Musante

Zitieren

APA

Braniff, N., Joshi, T., Cassidy, T., Trogdon, M., Kumar, R., Poels, K., Allen, R., Musante, C. J., & Shtylla, B. (2025). An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpoints. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13270

Vancouver

Braniff N, Joshi T, Cassidy T, Trogdon M, Kumar R, Poels K, et al. An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpoints. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.13270

BibTeX
@article{Braniff2025,
  author = {Braniff, Nathan and Joshi, Tanvi and Cassidy, Tyler and Trogdon, Michael and Kumar, Rukmini and Poels, Kamrine and Allen, Richard and Musante, Cynthia J and Shtylla, Blerta},
  title = {An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpoints},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.13270}
}
Kostenlos starten →